{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-074678","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2026-07-02T14:30:00+00:00","discovered_at":"2026-07-02T14:31:01.670810+00:00","generated_at":"2026-07-02T14:31:05.259849+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Unicycive Therapeutics reports preliminary Q2 2026 cash balance of $61.4M","bullets":["Ending cash balance of approximately $61.4 million as of June 30, 2026.","Preliminary, unaudited results for the second quarter ended June 30, 2026.","No other financial details or comparisons provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-074678","json":"https://secwatch.observer/filing/0001213900-26-074678.json","markdown":"https://secwatch.observer/filing/0001213900-26-074678.md","text":"https://secwatch.observer/filing/0001213900-26-074678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026074678/0001213900-26-074678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026074678/ea0296892-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T14:31:05.259849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}